Will a second prophylactic treatment with a higher dosage of the same antidepressant either prevent or delay new depressive episodes?

Psychiatry Research

Volumn 96, Issue 1, 2000, Pages 81-85

  Franchini, Linda ^a   Rossini, David ^a   Bongiorno, Fanny ^a   Spagnolo, Chiara ^a   Smeraldi, Enrico ^a   Zanardi, Raffaella ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Long term treatment; Recurrence; Selective serotonin reuptake inhibitors; Unipolar depression

Indexed keywords

ANTIDEPRESSANT AGENT; FLUVOXAMINE; PAROXETINE; SERTRALINE;

ADULT; ARTICLE; DEPRESSION; DOSE RESPONSE; FEMALE; HUMAN; INFORMED CONSENT; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROPHYLAXIS; RECURRENT DISEASE;

ADULT; DEPRESSIVE DISORDER; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUVOXAMINE; HUMANS; MALE; MIDDLE AGED; PAROXETINE; PROPORTIONAL HAZARDS MODELS; RECURRENCE; RISK FACTORS; SEROTONIN UPTAKE INHIBITORS; SERTRALINE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 0034715153     PISSN: 01651781     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-1781(00)00188-8     Document Type: Article

References (24)

1. Cutler N.R., Post R.M. Life course of illness in untreated manic-depressive patients. Comprehensive Psychiatry. 23:1982;101-115.
2. Doogan D.P., Caillard V. Sertraline in the prevention of depression. British Journal of Psychiatry. 160:1992;217-222.
3. Fava G.A., Rafanelli C., Grandi S., Conti S., Belluardo P. Prevention of recurrent depression with cognitive behavioral therapy. Archives of General Psychiatry. 55:1998;816-820.
4. Franchini L., Zanardi R., Gasperini M., Perez J., Smeraldi E. Fluvoxamine and lithium in long-term treatment of unipolar subjects with high recurrence rate. Journal of Affective Disorders. 38:1996;67-69.
5. Franchini L., Gasperini M., Perez J., Smeraldi E., Zanardi R. A double-blind study of long-term treatment with sertraline or fluvoxamine for prevention of highly recurrent unipolar depression. Journal of Clinical Psychiatry. 58:1997;104-107.
6. Franchini L., Gasperini M., Perez J., Smeraldi E., Zanardi R. Dose response efficacy of paroxetine in preventing depressive recurrences: a randomized, double-blind study. Journal of Clinical Psychiatry. 59:1998;229-232.
7. Franchini L., Zanardi R., Gasperini M., Smeraldi E. Two-year maintenance treatment with citalopram 20 mg in unipolar subjects with high recurrence rate. Journal of Clinical Psychiatry. 6:1999;861-864.
8. Frank E., Kupfer D.J., Perel J.M., Cornes C., Jarrett D.B., Mallinger A.G., Thase M.E., McEachran A.B., Grochocinski V.J. Three-year outcomes for maintenance therapies in recurrent depression. Archives of General Psychiatry. 47:1990;1093-1099.
9. Frank E., Kupfer D.J., Perel J.M., Cornes C., Mallinger A.G., Thase M.E., McEachran A.B., Grochocinski V.J Comparison of full-dose versus half-dose pharmacotherapy in the maintenance treatment of recurrent depression. Journal of Affective Disorders. 27:1993;139-145.
10. Gasperini M., Scherillo P., Manfredonia M.G., Franchini L., Smeraldi E. A study of relapses in subjects with mood disorder on lithium treatment. European Neuropsychopharmacology. 3:1993;103-110.
11. Judd L.L., Akiskal H.S., Maser J.D., Zeller P.J., Endicott J., Coryell W., Paulus M.P., Kunovac J.L., Leon A.C., Mueller T.I., Rice J.A., Keller M.B. Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictors of rapid relapse. Journal of Affective Disorders. 50:1998;97-108.
12. Keller M.B., Shapiro R.W., Lavori P.W., Wolfe N. Relapse in major depressive disorder: analysis with the life table. Archives of General Psychiatry. 39:1982;911-915.
13. Keller M.B., Lavori P.W., Lewis C.E., Klerman G.L. Predictors of relapse in major depressive disorder. Journal of the American Medical Association. 250:1983;3299-3304.
14. Kupfer D.J. Long-term treatment of depression. Journal of Clinical Psychiatry. 52:1991;28-34.
15. Lucca, A., Gentilini, G., Lopez Silva, S., Soldarini, A., 2000. A simultaneous determination of human plasma levels of four selective serotonin reuptake inhibitors by high-performance liquid chromatography. Therapeutic Drug Monitoring, in press.
16. Montgomery S.A., Dufour H., Brion S. The prophylactic efficacy of fluoxetine in unipolar depression. British Journal of Psychiatry. 153:1988;69-76.
17. Montgomery S.A., Doogan D.P., Burnside R. The influence of different relapse criteria on the assessment of long-term efficacy of sertraline. International Clinical Psychopharmacology. 6(Suppl. 2):1991;37-46.
18. Montgomery S.A., Montgomery D.B. Prophylactic treatment in recurrent unipolar depression. Montgomery S.A., Rouillon F. Long-term Treatment of Depression. 1992;53-79 Wiley, New York.
19. Montgomery S.A., Dunbar G.C. Paroxetine is better than placebo in relapse prevention and the prophylaxis of recurrent depression. International Clinical Psychopharmacology. 8:1993;189-195.
20. Montgomery S.A., Rasmussen J.G.C., Tanghoj P. A 24 week study of 20 mg citalopram, 40 mg citalopram and placebo in the prevention of relapse of major depression. International Clinical Psychopharmacology. 8:1993;181-188.
21. Prien R.F., Klett C.J., Caffey E.M. Lithium carbonate and imipramine in the prevention of affective episodes. Archives of General Psychiatry. 29:1973;420-425.
22. Sacchetti E., Conte G., Guarneri L. Are SSRI antidepressants a clinically homogeneous class of compounds? The Lancet. 344:1994;126-127.
23. Terra J.L., Montgomery S.A. Fluvoxamine prevents recurrence of depression: results of a long-term, double-blind, placebo-controlled study. International Clinical Psychopharmacology. 13:1998;55-62.
24. Zis P., Goodwin F.K. Major affective disorder as a recurrent illness. Archives of General Psychiatry. 36:1979;835-839.